Protagonist Therapeutics PTGX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's restricted cash?
- Protagonist Therapeutics (PTGX) reported restricted cash of $288K in Q1 2026.
- How has Protagonist Therapeutics's restricted cash changed year-over-year?
- Protagonist Therapeutics's restricted cash increased by 28.0% year-over-year, from $225K to $288K.
- What is the long-term trend for Protagonist Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's restricted cash has grown at a 95.7% compound annual growth rate (CAGR), from $10K to $287K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.